Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Organic Chemistry

Show all topics

DOI

10.1016/s2152-2650(24)00956-x